Monoclonal Antibodies (mAbs)

Monoclonal Antibodies (mAbs)

Eurofins CDMO Alphora accelerates the development & manufacturing of monoclonal antibody (mAb) with robust upstream and downstream expertise.

Our 200 L fed-batch and perfusion systems enable flexible batch sizes and scalable processes, supported by growth media optimization, cell banking, and single-use processing trains designed to minimize contamination risk. Leveraging Design of Experiments (DoE) methodologies, we optimize cell culture conditions and purification strategies for mAbs, ADCs, recombinant proteins, and other complex biologics. With GMP production expansion to 2000 L by 2026—our team ensures efficient scale-up and regulatory compliance from early-phase through commercialization.

Growth media optimisation

To maximise product yield, Eurofins CDMO provides titer optimisation for cell culture media  

Cell Banking

With extensive capabilities for development, manufacturing and characterisation of cell banks, Eurofins CDMO offers cell banking services for research cell banks (RCBs)

Cell Storage

Eurofins CDMO provides customised services according to client needs, and can efficiently store cell research cell banks (RCBs), Master Cell Banks (MCBs) and Working Cell Banks (WCBs)

Process development and scale-up

Using Design of Experiments (DoE) approach, Eurofins CDMO integrates, single-use processing trains to develop processes that simplify manufacturing and reduce contamination risks with expertise in Risk Group 2 for exosomes, VLPs, EVLPs, ADCs, mAbs and recombinant proteins

Upstream processing

Using our expertise in cell line characteristics, we design and optimise cell culture conditions (media, feeds, and process parameters) to drive superior cell growth, viability, and specific productivity of any target biologic. Our experts are experienced in developing and implementing both high-performing fed-batch processes for maximising volumetric productivity and advanced perfusion strategies for intensified, continuous manufacturing, enabling higher cell densities and increased product throughput. 

Downstream processing

Our DSP team has both width and depth in experience with purification of a wide range of proteins from a multitude of feedstocks.

GMP production

Eurofins CDMO can support clinical manufacturing up to 200L scale. By April 2026 the production capacity will increase to 2000L scale with the addition of a new, full single use production train. 

Analytical support

Analytical method development, GMP method validation, release and stability testing to support upstream and downstream process analytical testing, and services to support characterisation of drug product and life cycle management of analytical methods